90
Views
5
CrossRef citations to date
0
Altmetric
Case Report

Reversible Hypotony and Choroidal Effusion Following the Use of Pergolide for Parkinson's Disease

&
Pages 423-425 | Received 26 Jul 2013, Accepted 22 Sep 2013, Published online: 19 Nov 2013

References

  • Elagouz M, Stanescu-Segall D, Jackson TL. Uveal effusion syndrome. Surv Ophthalmol 2010;55:134–145
  • Shaunak S, Wilkins A, Pilling JB, et al. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 1999;66:79–81
  • Bianchi M, Castiglioni MG. Refractory generalized edema; An infrequent complication of long-term pergolide treatment for Parkinson disease. Clin Neuropharmacol 2005;28(5):245–246
  • Perez-Lloret S, Bondon-Guitton E, Rascol O, et al. Adverse drug reactions to dopamine agonists: A comparative study in the French Pharmacovigilance Database. Movement Disorders 2010;12:1876–1880
  • Al-Sereitt MR, Quik RFP, Turner P. The effect of a single oral dose of pergolide on intraocular pressure and pupil diameter. Br J Clin Pharmac 1989;28:263–268
  • Potter DE, Burke JA. Effects of ergoline derivatives on intraocular pressure and iris function in rabbits and monkeys. Curr Eye Res 1983;2:281–288
  • Takusagawa HL, Hunter R, Jue A, et al. Bilateral uveal effusion and angle-closure glaucoma associated with bupropion use. Arch Ophthalmol 2012;130(1):120–122

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.